Earth Science Tech Inc. (OTC: ETST) held its first annual meeting of stockholders virtually on August 31, 2026, where shareholders approved several key proposals that could significantly alter the company's capital structure and market presence. The approvals signal a concerted effort to meet the listing standards of a national exchange such as Nasdaq or the New York Stock Exchange, a move that would enhance the company's visibility and access to institutional investors.
Shareholders authorized the Board of Directors to pursue a reverse stock split within a 12-month period, if deemed necessary to satisfy the minimum bid price requirement for uplisting. The decision on whether to execute the split remains with the Board, which will assess market conditions and the company's progress toward meeting exchange criteria. A reverse split is often a prerequisite for companies trading on the over-the-counter market to qualify for national exchange listing, as it can boost the per-share price to required levels. However, such splits can also be perceived negatively if not accompanied by strong fundamentals, making the Board's discretion critical.
In a separate but related vote, stockholders authorized the Board's Independent Special Committee to negotiate the retirement of the Series B Preferred Stock. This retirement would eliminate the company's current dual-class voting structure, a governance feature that often concentrates voting power in the hands of a few insiders. Removing the dual-class structure could make ETST more attractive to a broader range of investors, including institutional shareholders who typically favor one-share-one-vote policies. The move aligns with increasing pressure from proxy advisors and exchanges to simplify voting rights.
Additionally, shareholders ratified the appointment of Semple, Marchal & Cooper LLP as an independent registered public accounting firm, re-elected seven director nominees, and approved a new non-dilutive executive compensation framework. The compensation framework, described as non-dilutive, likely ties executive pay to performance metrics without issuing additional shares, preserving shareholder value. These measures collectively demonstrate a commitment to strong corporate governance and financial discipline, which are essential for a successful uplisting.
Giorgio R. Saumat, CEO and Chairman of the Board, emphasized that he will not support a reverse split unless it is clearly necessary for the uplisting. His stance may reassure shareholders concerned about the potential downsides of a split. The company's strategic focus on healthcare, pharmacy, and telemedicine positions it in a growing sector, but uplisting to a national exchange would provide greater liquidity and credibility, potentially attracting more research coverage and investment.
For more details on the meeting outcomes, shareholders can refer to the company's newsroom at https://ibn.fm/ETST. The full voting results are also available in the press release at https://ibn.fm/HIqJ9.
The implications of these approvals extend beyond immediate compliance. If ETST successfully uplists, it could gain access to a larger pool of investors, including those who are restricted from investing in OTC-traded securities. The elimination of the dual-class structure may also reduce the risk of governance-related discounts in the company's valuation. However, the reverse split remains a double-edged sword; while it can facilitate uplisting, it may also signal underlying weakness if not backed by operational improvements. The coming months will be crucial as the Board evaluates whether to proceed with the split and negotiates the Series B retirement. Investors will be watching closely for further announcements regarding the timeline and any potential impact on share price and liquidity.
